The anti-PS monoclonal antibody Bavituximab has been used in a number of clinical trials as an anti-cancer agent, and its use in targeting viral infections such as HIV-1 (145), Pichinde virus (as a model for Lassa fever virus), and CMV (146) has been investigated. This evidence concerns the gene PRB2 and viral infectious disease.